DiaMedica Therapeutics Inc.
DMAC
$3.53
-$0.01-0.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.23% | 0.80% | -22.20% | 8.51% | 27.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.96% | 33.47% | 18.92% | 3.98% | 47.19% |
| Operating Income | -43.96% | -33.47% | -18.92% | -3.98% | -47.19% |
| Income Before Tax | -53.55% | -40.39% | -14.36% | 2.30% | -37.26% |
| Income Tax Expenses | -59.09% | 0.00% | 0.00% | 0.00% | 214.29% |
| Earnings from Continuing Operations | -53.07% | -40.33% | -14.34% | 2.30% | -37.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.07% | -40.33% | -14.34% | 2.30% | -37.59% |
| EBIT | -43.96% | -33.47% | -18.92% | -3.98% | -47.19% |
| EBITDA | -43.97% | -33.48% | -18.88% | -3.97% | -47.21% |
| EPS Basic | -35.94% | -24.62% | 17.94% | 31.91% | 4.30% |
| Normalized Basic EPS | -36.33% | -24.63% | 17.99% | 31.91% | 4.52% |
| EPS Diluted | -35.94% | -24.62% | 17.94% | 31.91% | 4.30% |
| Normalized Diluted EPS | -36.33% | -24.63% | 17.99% | 31.91% | 4.52% |
| Average Basic Shares Outstanding | 12.61% | 12.65% | 39.38% | 43.51% | 43.75% |
| Average Diluted Shares Outstanding | 12.61% | 12.65% | 39.38% | 43.51% | 43.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |